eISSN: 1896-9151
ISSN: 1734-1922
Archives of Medical Science
Current issue Archive Manuscripts accepted About the journal Special issues Editorial board Abstracting and indexing Subscription Contact Instructions for authors
SCImago Journal & Country Rank
6/2017
vol. 13
 
Share:
Share:
more
 
 
abstract:
Basic research

Tissue expression of β-catenin and E- and N-cadherins in chronic hepatitis C and hepatocellular carcinoma

Aldona Kasprzak, Karol Rogacki, Agnieszka Adamek, Karolina Sterzyńska, Wiesława Przybyszewska, Agnieszka Seraszek-Jaros, Celina Helak-Łapaj, Przemysław Pyda

Arch Med Sci 2017; 13, 6: 1269–1280
Online publish date: 2017/01/19
View full text
Get citation
ENW
EndNote
BIB
JabRef, Mendeley
RIS
Papers, Reference Manager, RefWorks, Zotero
AMA
APA
Chicago
Harvard
MLA
Vancouver
 
Introduction: The role of the Wnt/β-catenin signalling pathway in HCV-associated hepatocellular carcinogenesis is still unknown.

Material and methods: This study aimed to perform quantitative analysis of immuno- and hybridocytochemical expression of β-catenin, E-cadherin and N-cadherin and HCV proteins (C, NS3, NS5A) in long-term (≥ 20 years) chronic hepatitis C (CH-C) (n = 54), hepatocellular carcinoma (HCC) (n = 61) and control liver (n = 8).

Results: Typical membranous expression of β-catenin in the control liver was significantly higher than in the CH-C and HCC groups. The mean β-catenin tissue expression in CH-C was similar to the control group, and significantly higher than that of HCC. E-cadherin expression was lower in CH-C than in the control and HCC. In HCC expression of both β-catenin and E-cadherin was significantly lower in comparison to controls. Positive correlations were found between β-catenin and E-cadherin (in CH-C and HCC), β-catenin and N-cadherin (HCC), and E- and N-cadherin expression (HCC). The altered liver expression of β-catenin, E and/or N-cadherin did not correlate with any clinicopathological characteristics in the examined groups. In CH-C a positive correlation was demonstrated between NS5A and β-catenin, and between all HCV proteins (C, NS3, NS5A) and E-cadherin expression.

Conclusions: Alterations in cellular locations of β-catenin and E-cadherin in CH-C and HCC pointed to structural disturbances in intercellular junctions in the livers and presence of the transcriptionally inactive form of β-catenin. The reduced expression of E-cadherin in long-lasting CH-C may represent an early indicator of the epithelial-mesenchymal transition. The most important role in modulation of the Wnt/β-catenin pathway in vivo is probably played by the NS5A viral protein.
keywords:

chronic hepatitis C, hepatocellular carcinoma, cadherin/catenin complex, NS3, NS5A and C protein, immuno- and hybridocytochemistry

references:
Selimovic D, El-Khattouti A, Ghozlan H, Haikel Y, Abdelkader O, Hassan M. Hepatitis C virus-related hepatocellular carcinoma: an insight into molecular mechanisms and theraupeutic strategies. World J Hepatol 2012; 4: 342-55.
Higgs MR, Lerat H, Pawlotsky JM. Hepatitis C virus-induced activation of beta-catenin promotes c-Myc expression and a cascade of pro-carcinogenetic events. Oncogene 2013; 32: 4683-93.
Hsu HC, Jeng YM, Mao TL, Chu JS, Lai PL, Peng SY. Beta-catenin mutations are associated with a subset of low-stage hepatocellular carcinoma negative for hepatitis B virus and with favorable prognosis. Am J Pathol 2000; 157: 763-70.
Hoshida Y, Nijman SM, Kobayashi M, et al. Integrative transcriptome analysis reveals common molecular subclasses of human hepatocellular carcinoma. Cancer Res 2009; 69: 7385-92.
Chen J, Liu J, Jin R, et al. Cytoplasmic and/or nuclear expression of beta-catenin correlate with poor prognosis and unfavorable clinicopathological factors in hepatocellular carcinoma: a meta-analysis. PLoS One 2014; 9: e111885.
Wong CM, Fan ST, Ng IO. Beta-catenin mutation and overexpression in hepatocellular carcinoma: clinicopathological and prognostic significance. Cancer 2001; 92: 136-45.
Cui J, Zhou XD, Liu YK, Tang ZY, Zile MH. Abnormal beta-catenin gene expression with invasiveness of primary hepatocellular carcinoma in China. World J Gastroenterol 2001; 7: 542-6.
Zhai B, Yan HX, Liu SQ, Chen L, Wu MC, Wang HY. Reduced expression of E-cadherin/catenin complex in hepatocellular carcinoma. World J Gastroenterol 2008; 14: 56665-73.
Cho SB, Lee KH, Lee JH, et al. Expression of E-and N-cadherin and clinicopathology in hepatocellular carcinoma. Pathol Int 2008; 58: 635-42.
Rogacki K, Kasprzak A, Stępiński A. Alterations of WNT/beta-catenin signaling pathway in hepatocellular carcinomas associated with hepatitis C virus. Pol J Pathol 2015; 66: 9-21.
Street A, Macdonald A, Crowder K, Harris M. The hepatitis C virus NS5A protein activates a phosphoinositide 3-kinase-depended survival signaling cascade. J Biol Chem 2004; 279: 12232-41.
Bedossa P, Poynard T. An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group. Hepatology 1996; 24: 289-93.
Sabattini E, Bisgaard K, Ascani S, et al. The EnVision++ system: a new immunohistochemical method for diagnostics and research. Critical comparison with the APAAP, ChemMate, CSA, LABC, and SABC techniques.
J Clin Pathol 1998; 51: 506-11.
Gurgul E, Kasprzak A, Bluszczyk A, et al. Ghrelin and obestatin in thyroid gland – immunohistochemical expression in nodular goiter, papillary and medullary cancer. Folia Histochem Cytobiol 2015; 53: 19-25.
Huang H, Fujii H, Sankila A, et al. Beta-catenin mutations are frequent in human hepatocellular carcinomas associated with hepatitis C virus infection. Am J Pathol 1999; 155: 1795-801.
Kasprzak A, Spachacz R, Wachowiak J, Stefańska K, Kaczmarek E, Zabel M. Tissue expression of interleukin 2 (IL-2) and IL-2 receptor (IL-2Ralpha/CD25) in non-Hodgkin’s B-cell lymphomas in children: correlation with clinical data. J Pediatr Hematol Oncol 2010; 32: 462-71.
Remmele W, Stegner HE. Recommendation for uniform definition of an immunoreactive score (IRS) for immunohistochemical estrogen receptor detection (ER-ICA) in breast cancer tissue. Pathologe 1987; 8: 138-40.
Cui J, Zhou X, Liu Y, Tang Z. Mutation and overexpression of beta-catenin gene may play an important role in primary hepatocellular carcinoma among Chinese people. J Cancer Res Clin Oncol 2001; 127: 577-81.
Tien LT, Ito M, Nakao M, et al. Expression of beta-catenin in hepatocellular carcinoma. World J Gastroenterol 2005; 11: 2398-401.
Joo M, Lee HK, Kang YK. Expression of beta-catenin in hepatocellular carcinoma in relation to tumor cell proliferation and cyclin D1 expression. J Korean Med Sci 2003; 18: 211-7.
Kondo Y, Kanai Y, Sakamoto M, et al. Beta-catenin accumulation and mutation of exon 3 of beta-catenin gene in hepatocellular carcinoma. Jpn J Cancer Res 1999; 90: 1301-9.
Mao TL, Chu JS, Jeng MY, Lai PL, Hsu HC. Expression of mutant nuclear beta-catenin correlates with non-invasive hepatocellular carcinoma, absence of portal vein spread, and good prognosis. J Pathol 2001; 193: 95-101.
Inagawa S, Itabashi M, Adachi S, et al. Expression and prognostic roles of beta-catenin in hepatocellular carcinoma: correlation with tumor progression and postoperative survival. Clin Cancer Res 2002; 8: 450-6.
Milward A, Mankouri J, Harris M. Hepatitis C virus NS5A protein interacts with beta-catenin and stimulates its transcriptional activity in phosphoinositide-3 kinase-dependent fashion. J Gen Virol 2010; 91: 373-81.
Park JY, Park WS, Nam SW, et al. Mutations of beta-catenin and AXIN 1 genes are a late event in human hepatocellular carcinogenesis. Liver Int 2005; 25: 70-6.
Ihara A, Koizumi H, Hashizume R, Uchikoshi T. Expression of epithelial cadherin and alpha and beta-catenins in nontumoral livers and hepatocellular carcinomas. Hepatology 1996; 23: 1441-7.
Guo C, Liu QG, Yang W, Zhang ZL, Yao YM. Relation among p130Cas, E-cadherin and beta-catenin expression, clinicopathologic significance and prognosis in human hepatocellular carcinoma. Hepatobiliary Pancreat Dis Int 2008; 7: 490-6.
Mima K, Hayashi H, Kuroki H, et al. Epithelial-mesenchymal transcition expression profiles as a prognostic factor for disease-free survival in hepatocellular carcinoma: clinical significance of transforming growth factor-beta-signaling. Oncology Lett 2013; 5: 149-54.
Arora P, Kim EO, Jung JK, Jang KL. Hepatitis C virus core protein downregulates E-cadherin expression via activation of DNA methyltransferase 1 and 3b. Cancer Lett 2008; 261: 244-52.
Ripoli M, Barbano R, Balsamo T, et al. Hypermethylated levels of E-cadherin promoter in Huh-7 cells expressing the HCV core protein. Virus Res 2011; 160: 74-81.
Quan H, Zhou F, Nie D, et al. Hepatitis C virus core protein epigenetically silences SFRP1 and enhances HCC aggressiveness by inducing epithelial-mesenchymal transition. Oncogene 2014; 33: 2826-35.
Bose SK, Meyer K, Di Bisceglie AM, Ray RB, Ray R. Hepatitis C virus induces epithelial-mesenchymal transition in primary human hepatocytes. J Virol 2012; 86: 13621-8.
Iqbal J, McRae S, Mai T, Banaudha K, Sarkar-Dutta M, Waris G. Role of hepatitis C virus induced osteopontin in epithelial to mesenchymal transition, migration and invasion of hepatocytes. PLoS One 2014; 9: e87464.
Li X, Chen Y, Ye W, et al. Blockade of CCN4 attenuates CCl4-induced liver fibrosis. Arch Med Sci 2015; 3: 647-53.
FEATURED PRODUCTS
Quick links
© 2018 Termedia Sp. z o.o. All rights reserved.
Developed by Bentus.
PayU - płatności internetowe